XML 56 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of Operations - Additional Information (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Apr. 19, 2017
Oct. 07, 2016
USD ($)
Jan. 31, 2018
USD ($)
Jul. 31, 2017
USD ($)
May 31, 2017
USD ($)
Aug. 31, 2015
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Date of incorporation             Apr. 30, 2004  
Date of operating commencement             Feb. 29, 2016  
Share split, conversion ratio 3.2              
Shares issued, net of issuance costs               $ 21,255
IPO                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Shares issued, net of issuance costs             $ 60,772  
IPO | Nasdaq                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Shares issued, net of issuance costs         $ 60,800      
Secondary Public Offering | Nasdaq | Subsequent Event                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Shares issued, net of issuance costs     $ 64,000          
UroGen Pharma Inc.                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Date of operating commencement             Feb. 29, 2016  
Allergan                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Consideration for sales and supporting services           $ 750    
Consideration received for license and future supply services   $ 17,500            
Milestone payment for licensing agreement       $ 7,500        
Allergan | Maximum                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Additional milestone payment to be paid   $ 207,500